Perspectives in antiviral chemotherapy.
The current progress in antiviral therapy is related to our better understanding of the viral multiplication, with potential targets for specific antiviral action at each step of the multiplication cycle inside the infected cell. Amantadine and Rimantadine are anti-influenza A drugs interfering with the penetration and the release of the virus. Most of the other antiviral drugs which are clinically available have the same target in common, namely the viral DNA polymerase. This holds true for modified nucleosides such as Acycloguanosine (Acyclovir), DHPG, Adenine-Arabinoside, Azidothymidine as well as pyrophosphate derivatives such as phosphonoformic acid. Unfortunately the antiviral chemotherapy must confront 3 obstacles: 1) a possible interference with the normal cellular metabolism, leading to residual cytotoxic side effects; 2) the genetic variability of the viruses, producing drug-resistant mutants and 3) the inability of any antiviral chemotherapeutic agent known to date to eradicate latent viral infection. A new approach of the control of latent infection is suggested with anti sense oligonucleotides of hybridons.
Groupe Hospitalier Pitié-Salpêtrière, Laboratoire de Bactériologie-Virologie, Paris, France.
J M
JM
Huraux
D
D
Ingrand
H
H
Agut
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D006801:Humans; D014777:Virus Diseases / Q000188:drug therapy* / Q000382:microbiology
D000998:Antiviral Agents